NCT07917182Not yet recruiting
Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
Population aging is transforming the epidemiological landscape of the Asia-Pacific region at an unprecedented pace. By 2050, more than one quarter of the region's population will be aged over 60, with 36.7% of countries projected to become" super-aged" societies. Within Hong Kong specifically, the age- and gender-adjusted prevalence rates of mild and major neurocognitive disorder (NCD) among adults aged 60 years or above have been estimated at 21.8% and 9.7%, respectively. The scale of this burden intensifies considerably within institutional care environments, where roughly seven in ten long-term care (LTC) residents have been identified as having major NCD. Recent local survey data also indicate that severe cognitive impairment affects up to 49.8% of residents aged above 85 years. Given current demographic trajectories, the number of individuals living with dementia in Hong Kong is projected to triple over the next two decades. These trends underscore an urgent, time-sensitive need for scalable, accurate, and population-appropriate tools for the early detection and prognostic stratification of cognitive impairment, tools that must be actionable at the point of care and deployable at population scale. This study aim to generate a large database of cognitive, neuroimaging, plasma biomarkers, lifestyle and psychological information of the subjects who suffered from neurocognitive disorders
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1600 (estimated)
- First submitted
- 22 Oct 2026
- Start date
- 30 Nov 2026
- Primary completion date
- 31 Dec 2031
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Alzheimer disease
- NCT number
- NCT07917182
What you commit to
- Study type: Observational
- Planned participants: 1600
- From 30 Nov 2026 to the primary completion date, 31 Dec 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Clinical diagnosis of a primary neurological disorder that could independently account for cognitive impairment, including but not limited to Huntington's disease, normal pressure hydrocephalus, prion disease (CJD or variants), multiple sclerosis or other demyelinating disease, epilepsy, and/or
- Know history of major depressive episodes, schizophrenia, bipolar disorder, and/or
- Know history of moderate-to-severe traumatic brain injury, brain tumor, and/or
Other
- Contraindication for MRI or PET.
Who the study is looking for
- Aged ≥ 40 years old; and
- Participants must have a study partner (spouse, relative, or other person in regular contact, ≥ 10 hours/week)who is willing and able to accompany participant to relevant visits and provide independent report on cognitive/functional/behavioral status (e.g., cognitive evaluation); and
- Visual and auditory acuity sufficient (with correction/hearing aids as needed) to complete neuropsychological testing as per examiner judgment; and
- A primary language of Cantonese.
Age in the registry: 40 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Chinese University of Hong Kong | Hong Kong | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.